citarinostat

Citarinostat (ACY-241) is an orally available, selective inhibitor of histone deacetylase 6 (HDAC6), with significantly higher selectivity for HDAC6 over other class I and II histone deacetylases. By inhibiting HDAC6, citarinostat disrupts the deacetylation of both histones and non-histone proteins such as tubulin and cortactin. This leads to epigenetic modulation that represses oncogene transcription while promoting tumor suppressor gene expression, resulting in inhibition of tumor cell division and induction of apoptosis. Citarinostat has demonstrated potential antineoplastic activity in preclinical models and is being investigated clinically for multiple myeloma, advanced solid tumors (including non-small cell lung cancer), often in combination with other agents such as pomalidomide or nivolumab[1][4][7]. The drug is under development by Celgene.

Other names

citarinostatHDAC-IN-2HDAC-IN2HDAC-IN 2